Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Click here to view

Presentation

Poster: Optimal Drug Product Presentation and Container Closure Selection for AAV-Based Genomic Medicines

Download PDF